2019 IPO

Galera Therapeutics Stock

Therapeutic agents for preventing damage due to radiation treatment of cancer

Sign up today and learn more about Galera Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Galera Therapeutics Stock

Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, its lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.

Funding History

January 2011$805K
September 2011$405K
December 2012$11.0M
August 2014$4.7M
March 2015$4.7M
October 2015$37.0M
February 2016$5.0M
November 2016$15.0M
September 2018$70.0M


President, Chief Executive Officer & Board of Directors

Mel Sorensen

Co-Founder & Chief Scientific Officer

Dennis P. Riley

Chief Medical Officer

Jon T. Holmlund

Executive Chair, Board of Directors

Robert Alan Beardsley

Founder, Executive Chair, Board of Directors

Robert Beardsley


Joel Sussman

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: